Neurocrine to raise $250m in public offering
This article was originally published in Scrip
Executive Summary
Neurocrine Biosciences is planning to raise $250m through a public offering of 6.9 million shares, in order to fund its R&D operations and expected commercialization efforts for lead drug NBI-98854.